Dossier assessment

Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
A14-01
Last updated

Report documents

  1. Extract of dossier assessment

    Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 337 kB, EN, not accessible
  2. Dossier assessment

    Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 776 kB, not accessible

Press releases

Trastuzumab emtansine: indication of major added benefit in metastatic breast cancer with previous anthracycline therapy

Added benefit not proven in three further subpopulations because appropriate comparator therapies were not implemented

Additional information

Federal Joint Committee (G-BA)

2014-06-19 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A14-01
Commission
Commission awarded on 27.11.2013 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-07
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form